Day One Biopharmaceuticals Ownership | Who Owns Day One Biopharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Day One Biopharmaceuticals Ownership Summary


Day One Biopharmaceuticals is owned by 59.23% institutional investors, 16.94% insiders, and 23.83% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 6.81% of DAWN shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.43% of its assets in Day One Biopharmaceuticals shares.

DAWN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockDay One Biopharmaceuticals59.23%16.94%23.83%
SectorHealthcare Stocks 232.80%10.63%-143.43%
IndustryBiotech Stocks 379.48%10.37%-289.85%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de7.04M6.81%$151.03M
Vanguard group6.28M6.08%$58.55M
Blackrock4.53M5.23%$62.47M
Glazer capital4.68M4.53%$100.42M
Fil4.13M4.00%$88.59M
Deerfield management company, l.p. (series c)3.72M3.60%$79.82M
Jpmorgan chase3.13M3.03%$67.15M
State street2.87M2.78%$61.53M
Balyasny asset management2.63M2.54%$56.29M
Aqr arbitrage2.46M2.38%$52.79M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Beryl capital management514.11K10.04%$11.02M
Versor investments lp123.67K6.49%$2.65M
Dafna capital management978.46K4.77%$20.98M
Water island capital944.25K2.26%$20.24M
Glazer capital4.68M2.13%$100.42M
First trust capital management1.50M1.69%$32.07M
Alpine associates management925.00K1.17%$19.83M
Slotnik capital166.84K1.05%$3.58M
Gabelli & co investment advisers325.35K1.03%$6.98M
Deerfield management company, l.p. (series c)3.72M0.94%$79.82M

Top Buyers

HolderShares% AssetsChange
Glazer capital4.68M2.13%4.68M
Fil4.13M0.07%4.13M
Jpmorgan chase3.13M0.00%3.09M
Aqr arbitrage2.46M0.87%2.46M
Ubs group2.31M0.01%2.13M

Top Sellers

HolderShares% AssetsChange
Atlas venture life science advisors---6.41M
Ra capital management---5.76M
Fmr23.64K--5.69M
Vestal point capital, lp---5.20M
Rubric capital management lp---3.38M

New Positions

HolderShares% AssetsChangeValue
Glazer capital4.68M2.13%4.68M$100.42M
Fil4.13M0.07%4.13M$88.59M
Aqr arbitrage2.46M0.87%2.46M$52.79M
Perceptive advisors1.76M0.74%1.76M$37.64M
Soros fund management1.54M0.36%1.54M$33.00M

Sold Out

HolderChange
Dunhill financial-1.00
Nelson, van denburg & campbell wealth management group-12.00
Northwestern mutual wealth management-14.00
Geowealth management-23.00
C m bidwell & associates-28.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025159-7.56%61,236,176-28.40%590.86%911.11%37-33.93%
Sep 30, 2025167-1.76%83,154,2761.47%801.28%87-12.12%5410.20%
Jun 30, 2025178-6.32%86,133,5140.67%831.20%101-6.48%5210.64%
Mar 31, 202519311.56%94,051,9090.33%910.97%10813.68%4720.51%
Dec 31, 2024170-3.41%93,046,5121.26%961.06%93-8.82%408.11%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard US Total Market Shares ETF2.46M2.43%522.40K
Vanguard Total Stock Mkt Idx Inv2.46M2.38%48.47K
Polar Capital Biotech S Inc2.11M2.06%-
iShares Russell 2000 ETF1.90M1.84%-15.51K
Pictet-Biotech P USD1.69M1.64%1.69M
Franklin US Small Cap Growth Equity1.61M1.59%130.60K
Franklin Small Cap Growth SMA1.61M1.59%1.61M
Franklin Biotechnology Discv A(acc)USD1.55M1.52%-
Franklin Small Cap Growth Adv1.48M1.45%-
Pictet Biotech1.37M1.40%1.37M

Recent Insider Transactions


DateNameRoleActivityValue
Feb 17, 2026Merendino Lauren Chief Commercial OfficerSell$67.45K
Feb 17, 2026Dubow Adam Gen Counsel & SecretarySell$74.19K
Feb 17, 2026York Charles N II COO and CFOSell$70.36K
Feb 17, 2026Bender Jeremy CHIEF EXECUTIVE OFFICERSell$179.34K
Feb 17, 2026VASCONCELLES MICHAEL Head of Research and Dev.Sell$31.65K

Insider Transactions Trends


DateBuySell
2026 Q2--
2026 Q1-5
2025 Q4-4
2025 Q3-4
2025 Q2-4

DAWN Ownership FAQ


Who Owns Day One Biopharmaceuticals?

Day One Biopharmaceuticals shareholders are primarily institutional investors at 59.23%, followed by 16.94% insiders and 23.83% retail investors. The average institutional ownership in Day One Biopharmaceuticals's industry, Biotech Stocks , is 379.48%, which Day One Biopharmaceuticals falls below.

Who owns the most shares of Day One Biopharmaceuticals?

Day One Biopharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (7.04M shares, 6.81%), Vanguard group (6.28M shares, 6.08%), and Blackrock (4.53M shares, 5.23%). Together, they hold 18.12% of Day One Biopharmaceuticals’s total shares outstanding.

Does Blackrock own Day One Biopharmaceuticals?

Yes, BlackRock owns 5.23% of Day One Biopharmaceuticals, totaling 4.53M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 62.47M$. In the last quarter, BlackRock decreased its holdings by -498K shares, a -9.90% change.

Who is Day One Biopharmaceuticals’s biggest shareholder by percentage of total assets invested?

Beryl capital management is Day One Biopharmaceuticals’s biggest shareholder by percentage of total assets invested, with 10.04% of its assets in 514.11K Day One Biopharmaceuticals shares, valued at 11.02M$.

Who is the top mutual fund holder of Day One Biopharmaceuticals shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Day One Biopharmaceuticals shares, with 2.43% of its total shares outstanding invested in 2.46M Day One Biopharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools